Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that Dapagliflozin, as a highly selective SGLT-2 inhibitor,38 may have the ability to influence the function of central autonomic control that results in neural activation related to BP and HR regulation.”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [38]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Kidney: Physiology and Pathophysiology
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-544_3 · Cited by 1,673
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Research works printed but not linked: 17
- Washburn W., 2007, 234th National ACS Meeting
- 2006, Diabetes Atlas
- Bertoni A. G., 2007, Diabetes Care
- Mueller G., 2002, Recent Res. Develop. Endocrinol., 3, 199
- Moe O. W., 2000, The Kidney, 375
- Wright E. M., 1993, Soc. Gen. Physiol. Ser., 48, 229
- Wright E. M., 1992, Acta Physiol. Scand., Suppl., 146, 201
- Wells R. G., 1992, Am. J. Physiol., 263, F459
- Santer R., 2000, J. Inher. Metab. Dis., 23, 178
- 2004, Chem. Abstr., 142, 94061
- 2004, Chem. Abstr., 141, 332411
- 2004, Chem. Abstr., 141, 123854
- 2003, Chem. Abstr., 138, 153771
- 2001, Chem. Abstr., 135, 273164
- 2001, Chem. Abstr., 135, 273163
- 2003, Chem. Abstr., 138, 221784
- 2004, Chem. Abstr., 141, 89317
Cited by
Items 601–684 of 684
Luo, H., Zang, Y., & Zhang, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00032-7
Higashibayashi, S. (2024) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.82.1052
Seki, M., Mulani, S. K., Yang, R., Shukla, G., Tapkir, S. R., Nandi, S., Kalita, S. J., & Mashima, K. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c02752
Ramu, C., Kumar, M. S., Shivakrishna, A., Kumaraguru, T., Ghosh, S., Reddy, C. R., & Sudhakar, G. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c02914
Rastogi, S. K., Odeh, M. A., & Rastogi, P. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00002-6 · Cited by 1
Sotagliflozin: a dual SGLT1/2 inhibitor, for full range of heart failure
Zheng, L., & Liang, Z. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00025-1
Mansour, S. M. A., Attia, A. A. E.-S. A., Elsherbiney, A. M. M., & Mohaseb, E. S. A. (2025) · Al-Azhar Assiut Medical Journal · doi:10.4103/azmj.azmj_57_25
Amine-Enabled Open–Close Skeletal Editing of Aldoses to Access 1,2-cis C-Furanosides
Sun, D., & He, G. (2026) · Synlett · doi:10.1055/a-2825-5453
Sodium glucose transporter 2 inhibitors for heart failure
Usuda, D., Furukawa, D., Imaizumi, R., Ono, R., Kaneoka, Y., Nakajima, E., Kato, M., Sugawara, Y., Shimizu, R., Inami, T., et al. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i3.118227
The Chemistry of Gliflozins: Recent Advancements in SGLT-2 Inhibitors
Samman, Singh, K., Hasan, S. M., Kumar, A., Kushwaha, S. P., Soni, P., Suvaiv, & Shahanawaz, M. (2026) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/0118715257423396260126091907
Synthesis and Immunostimulatory Activity of Xanthone C -β - Glucosides
Long, G., Zeng, L., Jiang, H., Zhao, J., Hu, Y., & Zhang, Y.-F. (2026) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6c00166
Chen, P.-Y., Chiang, Y., Lin, C.-H., Hsieh, M., & Lin, H. (2026) · Organic & Biomolecular Chemistry · doi:10.1039/d6ob00392c
Effect of Dapagliflozin on Macrophages and its Impact in Obesity and Diabetes: An In Vitro Study
Tiwari, S., K., G. V., Shukla, A., & K., U. S. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.21s.51
Abdou, F. Y., Shibrya, E. E., Ali, M., Arafa, N. M., & Abdelaleem, R. M. A. (2026) · Archives of Medical Research · doi:10.1016/j.arcmed.2026.103438
Pharmacological and Nanotechnological Insights into SGLT-2 Inhibitors for Type 2 Diabetes Management
Singh, S., Grewal, S., Sharma, N., Kishore, L., Kumar, P., Verma, S., & Gupta, S. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs151.025
Ni‐Catalyzed Selective Crosscoupling for Diarylmethane‐Containing Boronic Ester Synthesis
Wan, H., Cui, Y., Liu, F., Pei, X., Jia, D., Zhu, Y., & Wang, X. (2026) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.70553
Scalable purification of an oily Ertugliflozin intermediate via cocrystallization
Li, C., Wang, R., Zhi, F., Zekun, J., Li, C., & Qiao, R. (2026) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2026.05.044
Search for New Inhibitors of SGLT2 Based on Virtual Screening and Structural Analysis
Karpova, A. P., Shmagai, L. M., & Karpov, P. A. (2026) · Cytology and Genetics · doi:10.3103/s0095452726030035
“Subsequently, by using phlorizin as a reference compound, the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation (www.mt-pharma.co.jp) synthesized the inhibitor T-1095, which inhibits human SGLT1 and SGLT2 with an IC50 in the range of 50–200 (Tsujihara et al., 1996; Oku et al., 1999).”
InfluentialSelective sugar transport supports Proteus mirabilis fitness in the urinary tract
Shea, A. E., Kuo, S., Gupta, S., Smith, S. N., Appaji, T., Mitchell, T. J., Mobley, H. L. T., & Pearson, M. M. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014324
“We accomplished this using the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin, which reduces renal glucose reabsorption leading to increased glucose concentrations in urine [64].”
Breaking barriers in pulmonary health of patients with metabolic diseases: senolytics and beyond
Rennerova, M., Žaloudíková, M., Haluzík, M., & Hubáčková, S. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1812724 · Cited by 1
“Dapagliflozin is a highly selective SGLT2 inhibitor particularly effective in alleviating glucotoxicity, supporting β -cell function, and improving insulin sensitivity, making it a suitable option for managing T2DM with insulin resistance or β -cell dysfunction (Meng et al., 2008; Han et al., 2008).”
Thomas, J., Subair, S., Mahin, A., Gopalakrishnan, A. P., Shivamurthy, P. B., Rajeev, A. C., & Raju, R. (2026) · Frontiers in Systems Biology · doi:10.3389/fsysb.2026.1780024
“Examples include the SGLT2 inhibitors canagliflozin (Nomura et al., 2010) and dapagliflozin (Meng et al., 2008) (SLC5A2), tiagabine (Meldrum and Chapman, 1999) (SLC6A1), atomoxetine (Ramoz et al., 2009) (SLC6A2), methylphenidate (Kasparbauer et al., 2015) (SLC6A3), and probenecid (García-Rodríguez…”
Recent Advances in Nonprecious Metal Catalysis
Berger, K. E., Faialaga, N. H., Hurtak, J. A., Li, R., Ma, X., Payne, J. L., Hall, J. R., & Wu, X. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.6c00229
Magnesium-carbon laminates enable nickel-catalyzed synthesis of aryl C -glycosides in flow
遠藤, 寛., Kodani, K., Sasaki, N., Nagaki, A., & Nokami, T. (2026) · Chemical Communications · doi:10.1039/d6cc04801c
Dapagliflozin Beyond Glucose Lowering: Mechanisms of Renal and Systemic Protection
Wise, M. L., & Alli, A. A. (2026) · Pathophysiology · doi:10.3390/pathophysiology33030068
“This research led to the development and clinical approval of several highly selective SGLT2 inhibitors, including empagliflozin [23], dapagliflozin [24], canagliflozin [25], and ertugliflozin [26], each of which demonstrated efficacy in lowering blood glucose via enhanced glycosuria [23–26].”
Vega, D. S., Oskoui, E., & Siskind, L. J. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_853
Zappaterra, F., Meola, D., Presini, F., Lerin, L. A., & Giovannini, P. P. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091166
“…cited clinically, dapagliflozin, is instructive precisely because it is not a releasing prodrug: the metabolically labile O -glucoside phlorizin was de-liberately replaced by a hydrolysis-resistant C-glucoside to prevent β -glucosidase cleavage, a chemical solution to a stability problem [116].”
Hilger, A., Adick, A., Putze, J., von Vietinghoff, S., & Dobrindt, U. (2026) · Scientific Reports · doi:10.1038/s41598-026-72071-3
“The synthetic analogs dapagliflozin 17 , canagliflozin 18 , empagliflozin 19 and ertugliflozin 20 are approved by the FDA 21 and were investigated in this study.”
BindingDB (2011) · UC San Diego · doi:10.7270/q2sx6dh1
BindingDB Entry 50044221: Synthetic approaches to the 2012 new drugs.
BindingDB (2015) · UC San Diego · doi:10.7270/q2ws8vs9
BindingDB (2011) · UC San Diego · doi:10.7270/q2nc61km
BindingDB (2011) · UC San Diego · doi:10.7270/q2c24wpz
BindingDB (2013) · UC San Diego · doi:10.7270/q26d5v36
BindingDB Entry 50018710: Current anti-diabetic agents and their molecular targets: A review.
BindingDB (2024) · UC San Diego · doi:10.7270/q29z9940
BindingDB (2011) · UC San Diego · doi:10.7270/q2959hvz
BindingDB (2012) · UC San Diego · doi:10.7270/q2fb53bq
BindingDB Entry 50027034: Design and synthesis of fluorescent SGLT2 inhibitors.
BindingDB (2010) · UC San Diego · doi:10.7270/q27944j7
BindingDB (2012) · UC San Diego · doi:10.7270/q2pg1s3w
BindingDB Entry 50033129: Discovery of non-glucoside SGLT2 inhibitors.
BindingDB (2011) · UC San Diego · doi:10.7270/q25q4wd2
BindingDB Entry 50032079: Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors.
BindingDB (2011) · UC San Diego · doi:10.7270/q2r78fdn
BindingDB Entry 50010930: Anti-diabetic drugs recent approaches and advancements.
BindingDB (2021) · UC San Diego · doi:10.7270/q2t43xn8
BindingDB (2014) · UC San Diego · doi:10.7270/q2tx3gsm
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
BindingDB (2014) · UC San Diego · doi:10.7270/q24j0gm7
BindingDB (2011) · UC San Diego · doi:10.7270/q2kk9c32
Metadata
- Authors
- Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., Zahler, R., Deshpande, P. P., Pullockaran, A., Hagan, D. L., Morgan, N., Taylor, J. R., Obermeier, M. T., Humphreys, W. G., Khanna, A., Discenza, L., Robertson, J. G., Wang, A., Han, S., Wetterau, J. R., Janovitz, E. B., Flint, O. P., Whaley, J. M., & Washburn, W. N.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Metabolic Diseases Chemistry, Process R & D, Metabolic Diseases Biology, Pharmacological Candidate Optimization, Drug Safety Evaluation, Research and Development, Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543
- Corresponding author
- Meng, Wei
- Washburn, William N.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-02-09
- Volume
- 51
- Issue
- 5
- Pages
- 1145-1149
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2026609170
- Cited by
- 634
- References
- 39
- Citations by year
- 2026: 32 · 2025: 35 · 2024: 28 · 2023: 23 · 2022: 35 · 2021: 32 · 2020: 40 · 2019: 34 · 2018: 26 · 2017: 22 · 2016: 35 · 2015: 44 · 2014: 40 · 2013: 36 · 2012: 43
- FWCI
- 35.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, antidiabetic drug discovery, blood glucose reduction, streptozotocin-induced hyperglycemia, ADME properties
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Animals, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Glucosides, Humans, Hypoglycemic Agents, Kidney, Stereoisomerism, Sodium-Glucose Transporter 2, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.